SEPT9 is a set of DNA methylation markers currently used as an FDA-approved diagnostic biomarker for CRC in combination with N-myc downstream-regulated gene 4 (NDRG4) and bone morphogenetic protein 3 (BMP3) [14]. The gene discussed is BMP3; the disease is colorectal carcinoma.